Company Information

CIN
Status
Date of Incorporation
31 August 2005
State / ROC
/ ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
86,471,520
Authorised Capital
120,000,000

Directors

Jagapathi Raju Sri Vatchavai
Jagapathi Raju Sri Vatchavai
Director/Designated Partner
over 2 years ago
Avinash Vatchavai
Avinash Vatchavai
Director/Designated Partner
almost 3 years ago
Sai Krishna Karuturi
Sai Krishna Karuturi
Director/Designated Partner
over 6 years ago
Abhinav Vatchavai
Abhinav Vatchavai
Director/Designated Partner
over 8 years ago
Narasimha Reddy Duthala
Narasimha Reddy Duthala
Director
over 20 years ago
Srinivas Isola
Srinivas Isola
Director
over 20 years ago
Rama Rao Venkata Karuturi
Rama Rao Venkata Karuturi
Director/Designated Partner
over 20 years ago

Past Directors

Christopher Newton Benny Job Devairakkam
Christopher Newton Benny Job Devairakkam
Additional Director
over 8 years ago
Satya Narayana Reddy Padala
Satya Narayana Reddy Padala
Director
about 10 years ago
Ranga Rao Ravipati
Ranga Rao Ravipati
Director
about 10 years ago
Amitabha Guha
Amitabha Guha
Director
about 15 years ago
Karunamay Lahiri
Karunamay Lahiri
Director
about 15 years ago
Sunil Unny Guptan
Sunil Unny Guptan
Director
about 15 years ago
Gopala Krishna Muddusetty .
Gopala Krishna Muddusetty .
Director
about 15 years ago
Pyar Ali Jiwani
Pyar Ali Jiwani
Additional Director
over 15 years ago
Rama Raju Vatsavai
Rama Raju Vatsavai
Director
over 20 years ago
Venkata Alluri Raju
Venkata Alluri Raju
Director
over 20 years ago
Murali Krishna Madala
Murali Krishna Madala
Director
over 20 years ago

Patents

A Process For Preparation Of 4 Fluoro Alpha [2 Methyl 1 Oxopropyl] Gamma Oxo N ß Diphenylbenzene Butane Amide

A process for preparation of 4-fluoro- α -[2-methyl-l-oxopropyl]-Y-oxo-N-β- diphenylbenzene butane amide also known as a diketone intermediate of atorvastatin, completely devoid of impurities 3,4-difluoro- α -[2-methyl-l-oxopropyl]-y-oxo-n-β-diphenylbenzene butane amide; methyl, 2{-2[-(4-fluorophenyl)-2-oxo-l-phenyl...

Method For Preparing 4 Oxime 5` (2 Methylpropionyl) Uridine, Intermediates Thereof And Process For Preparing The Same

The present disclosure relates to an efficient method for preparing 4-oxime-5`-(2- methylpropionyl) uridine compound in substantially pure form and high yield suitable for commercial scale; a novel intermediate N'-(1,2-dihydro-1-((2R,3R,4S,5R)-tetrahydro-3,4-dihydroxy-5-(hydroxymethyl) furan-2-yl)-2-oxopyrimidin-4...

Impurity Controlled And Cost Effective Process For The Preparation Of Rosuvastatin Intermediate

The present invention application provides impurity-controlled and cost-effective process for the preparation of Rosuvastatin intermediate compound of formula (I) in high yields which is suitable for manufacturing in commercial scale. formula (I)

An Impurity Controlled Process For The Preparation Of 4,6 Dichloro 2 (Propylthio)pyrimidin 5 Amine A Ticagrelor Intermediate

The present application provides an impurity controlled process for the preparation of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine compound of formula (I), in high yields and purity, which is suitable for manufacturing in commercial scale.

Improved Process For The Preparation Of Bempedoic Acid

The present application provides an improved process for the preparation of Bempedoic acid compound of formula I. formula (I)

A Process For The Preparation Of Tert Butyl 5 Hydroxy 3 Oxohexanoate Compounds

The present invention relates to an improved process for the preparation of tert-butyl 5-hydroxy-3-oxohexanoate compound of formula (I) wherein: R1 is CN, halogen, or O-protecting group. (I) The tert-butyl 5-hydroxy-3-oxohexanoate compound of formula (I) is the key intermediate for the preparation of atorvastat...

Continuous Flow Process For The Preparation Of Tert Butyl 5 Hydroxy 3 Oxohexanoate Compounds

The present invention relates to a continuous flow process for the preparation of tert-butyl 5-hydroxy-3-oxohexanoatecompound of formula (I) wherein: R1 is CN, halogen or O-protecting group. (I) The tert-butyl 5-hydroxy-3-oxohexanoatecompound of formula (I) is the key intermediate for the preparation of atorvas...

An Improved Process For The Preparation Of Chiral Diol Sulfones

The present application provides an improved process for the preparation of chiral diol sulfones of formula (I) which are useful as potential intermediates for the preparation of Rosuvastatin in high yields and suitable for manufacturing in commercial scale.

Novel And Cost Effective Process For The Preparation Of Sitagliptin Intermediate 3 (Trifluoromethyl) 5,6,7,8 Tetrahydro [1,2,4]Triazolo[4,3 A]Pyrazine Hydrochloride

The present invention provides a novel and cost effective process for the preparation of Sitagliptin intermediate (3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride) which is suitable to manufacture in commercial scale. formula (I)

An Improved Process For The Preparation Of Chiral Diol Sulfones

The present application provides an improved process for the preparation of chiral diol sulfones of formula (I) which are useful as potential intermediates for the preparation of Rosuvastatin in high yields and suitable for manufacturing in commercial scale. Formula (I)

A Cost Effective And Improved Process For The Preparation Of Statin Advanced Intermediates

The present invention relates to a process for the preparation of statin advanced intermediates by using Julia-Kocienski reaction between an aldehyde and a sulfone derivative in the presence of combination of solvents and a metal hydroxy base. The resulting derivatives are advanced intermediates for statin type comp...

Improved Process For The Preparation Of Sitagliptin Intermediate 3 (Trifluoromethyl) 5,6,7,8 Tetrahydro [1,2,4]Triazolo[4,3 A]Pyrazine Hydrochloride

The present invention provides an improved process for the preparation of Sitagliptin intermediate (3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride) which is suitable to manufacture in commercial scale. formula (I)

Novel Process For The Preparation Of Bempedoic Acid

The present invention application relates to cost effective and commercially viable process for the preparation Bempedoic acid compound of formula I. Formula I

Improved Process For The Preparation Of Substantially Pure 4 Bromo 1 Chloro 2 (4 Ethoxybenzyl)benzene A Dapagliflozin Intermediate

The present invention provides improved process for the preparation of substantially pure 4-bromo-1-chloro-2-(4-ethoxybenzyl) benzene a dapagliflozin intermediate compound of formula (I) which is suitable to manufacture in commercial scale. Formula (I)

A Novel Process For The Preparation Of Bexagliflozin A Sglt2 Inhibitor And Its Intermediates Thereof

The present disclosure provides a novel process for the preparation of Bexagliflozin, (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol and its salts, solvates compound of formula (I) and its intermediates which is suitable to manufacture in comme...

Improved Process For The Preparation Of High Pure (1 R,2 S) 2 (3,4 Difluorophenyl) Cyclopropan 1 Amine Hydrochloride A Ticagrelor Intermediate

The present invention provides improved process for the preparation of substantially pure (1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine hydrochloride - a ticagrelor intermediate compound of formula (I) which is suitable to manufacture in commercial scale. Formula (I)

Improved Process For The Preparation Of 3 Aminopiperidine 2,6 Dione Hydrochloride A Lenalidomide And Pomalidomide Intermediate

The present invention provides improved process for the preparation of 3-aminopiperidine-2,6-dione hydrochloride a lenalidomide and pomalidomide intermediate compound of formula (I) which is suitable to manufacture in commercial scale.

An Improved Of Process For The Eco Friendly Preparation Of (S) 3 (4 (5 Bromo 2 Chlorobenzyl)phenoxy)tetrahydrofuran A Empagliflozin Intermediate

The present invention provides a process for the preparation of (s)-3-(4-(5-bromo-2-chlorobenzyl)phenoxy)tetrahydrofuran a empagliflozin intermediate compound of formula (I) which is suitable to manufacture in commercial scale.
The present invention provides an improved process for the preparation of substantially pure 2-(((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethan-1-ol - a ticagrelor intermediate compound of formula (I) which is suitable to manufacture in commercial scale. ...

A Process For The Preparation Of A Sglt2 Inhibitor And Its Intermediates Thereof

Provides an improved process for the preparation of Bexagliflozin, (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol and its salts, of compound of formula (I) and its intermediates which is suitable to manufacture in commercial scale. Formula (...

A Process For The Preparation Of Bexagliflozin A Sglt2 Inhibitor And Its Intermediates Thereof

The present invention relates to a process for the preparation of(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol compound of formula (I) which is suitable to manufacture in commercial scale. Formula (I)

A One Pot Process For The Preparation Of A Platelet Aggregation Inhibitor And Intermediates Thereof

The present invention provides a one-pot process for the preparation of substantially pure (1R,2R,3S,5R)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol - a ticagrelor compound of formula (I) which is suitable t...

A Novel Process For Preparation Of Sglt2 Inhibitor And Its Intermediates Thereof

provides a novel process for the preparation of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol; Bexagliflozin and its salts, solvates of compound of formula (I) and its intermediates which is suitable to manufacture in commercial scale. Fo...

Registered Trademarks

Vijayasri Vijayasri Organics

[Class : 5] Pharmaceuticals Preparations

Vijayasri Vijayasri Organics

[Class : 1] Chemicals.

Charges

16 August 2022
State Bank Of India
0
30 November 2015
Others
0
29 January 2007
State Bank Of India
0
21 February 2022
State Bank Of India
0
16 August 2022
State Bank Of India
0
30 November 2015
Others
0
29 January 2007
State Bank Of India
0
21 February 2022
State Bank Of India
0
16 August 2022
State Bank Of India
0
30 November 2015
Others
0
29 January 2007
State Bank Of India
0
21 February 2022
State Bank Of India
0